PDAC patients with high PD-L1 levels may not respond to PD-L1 therapy, due to the surge in the number of tumor immunosuppressive cells, such as the high infiltration of Tregs/MDSCs/TAMs, where TGFβ stimulates dendritic cells to induce immunosuppression (236). Here, TGFB1 is linked to neoplasm.